Fierce BioTech

MAY 30, 2024

Quantify Cancer With Methylation-Based ctDNA Detection Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively.

Clinical Trials 52

Clinical Trials DNA Trials Therapies 52

PPD

DECEMBER 16, 2024

Internal costs: The complexity of protocol designs a necessity for innovative therapies often requires more diverse patient populations, more extensive data collection and sophisticated trial methodologies, all of which demand higher financial outlays. Nearly 39% of sponsors cite these costs as primarily driven by complex protocols.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

The Pharma Data

OCTOBER 14, 2020

“We look forward to continuing to advance apraglutide and to preparing our organization to bring a potential best-in-class therapy to people living with SBS.” . BASEL, Switzerland , Oct. chief executive officer of VectivBio. managing director at Versant Ventures and chairman of the board of directors at VectivBio.

Disease 52

Disease Treatment Therapies Production 52

Fierce BioTech

JULY 25, 2023

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

Pharma Companies 52

Pharma Companies Government Therapies Disease 52

Fierce BioTech

MARCH 28, 2024

How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies Early involvement of Medical Affairs in advanced therapies is pivotal. Download to learn how Medical Affairs redefines healthcare and improves patient outcomes. Download to learn how Medical Affairs redefines healthcare and improves patient outcomes.

Biosimilars 52

Biosimilars Therapies Disease Drugs 52

The Pharma Data

NOVEMBER 26, 2020

(NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

JANUARY 27, 2021

HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). CAMBRIDGE, Mass. ROTTERDAM, Netherlands and SUZHOU, China , Jan. ” he added.

Therapies 40

Therapies Treatment International Licensing 40

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif.

Therapies 52

Therapies Production Government Disease 52

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

JANUARY 9, 2021

(NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.

Therapies 52

Therapies Trials Clinical Trials Treatment 52

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Disease 40

Disease Science Clinical Development Treatment 40

The Pharma Data

NOVEMBER 25, 2020

CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique properties for treatment of inflammatory diseases. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. About BioInvent. Cantargia AB (publ), reg.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

Drug Channels

FEBRUARY 6, 2024

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and the Rare Disease Summit three influential access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships. What is Access USA?

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Pharma Companies Disease 40

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

NOVEMBER 19, 2020

Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will participate in a virtual fire side chat at the 3 rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:55 a.m. .

Clinical Trials 52

Clinical Trials Therapies Disease Trials 52

PPD

SEPTEMBER 25, 2023

Historically, clinical trial populations were almost exclusively comprised of white, male participants,  exacerbating gaps in knowledge of diseases and conditions , preventive factors and treatment effectiveness. DOWNLOAD THE FULL REPORT The post New Report Reveals Trends, Opportunities in Drug Development appeared first on PPD Inc.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

The Pharma Data

OCTOBER 20, 2020

CureLab’s partners in the region will test the efficacy of the company’s DNA-based products against cancers and non-cancerous diseases of chronic inflammation. “There are horrible diseases that are dominant in the GCC region and rarely seen in the West,” said Jihad Fakhreddine. BOSTON , Oct. Source link.

DNA 52

DNA Hospitals International Trials 52

The ChEMBL-og

MAY 13, 2021

This paper on the 'Identification of the Core Chemical Structure in SureChEMBL Patents' has recently been published by Maria Falaguera and Jordi Mestres, and the resulting data set is available to download from the SureChEMBL FTP site: [link]. As mentioned above, this data set can be downloaded from SureChEMBL. of the total molecules).

Small Molecule 52

Small Molecule Therapies Disease Drugs 52

The Pharma Data

JANUARY 22, 2021

Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month. Since lupus impacts people differently and can change over time, a multidisciplinary team approach is going to be key to ensuring better overall care and to minimizing end-stage kidney disease.”

Research 52

Research Treatment FDA Approval Disease 52

The Pharma Data

JANUARY 13, 2021

Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. . NEW YORK , Jan. MindMed Co-CEO J.R. ” Robert Barrow Bio : Mr. .”

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

DECEMBER 9, 2020

The targeted indication is for treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The following files are available for download: View original content: [link].

FDA Approval 40

FDA Approval Therapies FDA Treatment 40

The Pharma Data

SEPTEMBER 16, 2020

along with members of Amgen ‘s clinical development team, will discuss the Phase 1 data being presented on the Company’s investigational half-life extended bispecific T-cell engager (BiTE ® ) immuno-oncology therapy targeting prostate-specific membrane antigen (PSMA). . View original content to download multimedia: [link].

Clinical Development 52

Clinical Development Therapies Disease Research 52

The Pharma Data

SEPTEMBER 15, 2020

Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Science Small Molecule 52

The Pharma Data

JANUARY 26, 2021

The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. View original content to download multimedia: [link]. Source link.

Therapies 52

Therapies Treatment Drugs Disease 52

The Pharma Data

OCTOBER 20, 2020

About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The following files are available for download: View original content: [link]. The information was submitted for publication at 08.30 CET on October 21, 2020.

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment FDA Therapies 52

KIF1A

AUGUST 28, 2024

KIF1A.ORG’s Chief Science Officer Dr. Dylan Verden will provide an overview of current areas of KAND therapeutic… Tuesday, September 24, 2024 5:00 pm – 6:00 pm Online via Zoom [link] ASO therapy: Positive Clinical Outcomes Observed We are thrilled to announce the publication of the **first-ever KAND ASO study** !

Therapies 52

Therapies Compound Screening Research Treatment 52

The Pharma Data

NOVEMBER 6, 2020

Parents and physicians should be aware that morning joint stiffness may indicate early disease symptoms of polyarticular JIA and serve as a more reliable indicator than pain. Polyarticular JIA is a chronic form of the disease with symptoms of pain, swelling, stiffness or warmth in four or more joints. NEW YORK , Nov. ” About HSS.

Nurses 52

Nurses Hospitals Disease Therapies 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. View original content to download multimedia: [link].

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. View original content to download multimedia: [link].

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52

The Pharma Data

DECEMBER 17, 2020

Opioid dependence is a serious, chronic, relapsing disease associated with a disproportionate amount of drug-related harm that includes infectious diseases and other health problems, mortality, unemployment, homelessness and social exclusion 6. The following files are available for download: View original content: [link].

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

The Pharma Data

DECEMBER 1, 2020

IsoPlexis’ Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research. View original content to download multimedia: [link]. BRANFORD, Conn. , BRANFORD, Conn. , SOURCE IsoPlexis.

Therapies 40

Therapies Disease Science Research 40

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. View original content to download multimedia: [link].

Treatment 40

Treatment Pharmaceuticals Drug Development Science 40

The Pharma Data

JANUARY 31, 2021

Many major disease targets are trimerization-dependent such as the tumor necrosis factor (TNF) superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells. View original content to download multimedia: [link]. About Dynavax.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Perficient: Drug Development

OCTOBER 5, 2023

These disabilities can be the result of various factors, including developmental disorders, acquired brain injuries, neurodegenerative diseases, and more. Sensory Processing Therapy : Offers a range of sensory-based activities and exercises to improve sensory processing skills.

Regulations 52

Regulations Therapies Production Disease 52

The Pharma Data

JANUARY 12, 2021

Our vision is to identify, develop and deliver to patients important new therapies for diseases with significant unmet need. We invite you to learn more about Adastra, our clinical and scientific partners and our journey to bring meaningful new therapies to patients, by visiting www.adastrarx.com. .

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

DECEMBER 2, 2020

“We are eager to learn more about which patients develop resistance to CDK 4 & 6 inhibitors, the potential underlying mechanisms, and ways in which such resistance can be overcome, in order to improve the application of this potentially life-prolonging therapy. . View original content to download multimedia: [link].

Research 52

Research Treatment Therapies Clinical Research 52

The Pharma Data

JANUARY 6, 2021

Currently, oral treatment options for plaque psoriasis are limited, and many patients with moderate-to-severe psoriasis are receiving systemic injectable therapies. UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases.

FDA Approval 52

FDA Approval FDA Clinical Development Treatment 52